This OMZO review covers one of the newest — and least documented — weight loss platforms we have scored. The pitch is simple: compounded semaglutide for $199 the first month, then a flat $299/month, with no contract, no membership fee, and no price increase as your dose rises. That refill lock is genuinely competitive.
The problem is everything around the price. OMZO has about 7 Trustpilot reviews, no BBB profile, unnamed compounding pharmacies, and refund terms that contradict its own money-back marketing. We score it 6.9/10 (Fair). Here is the full breakdown, verified against OMZO’s own pages in July 2026.
What Is OMZO?
OMZO (omzo.com) is a US telehealth platform selling clinician-prescribed GLP-1 weight loss programs: compounded semaglutide injections, compounded tirzepatide, oral GLP-1 dissolvable tablets, and brand-name Ozempic and Zepbound options. It also runs side verticals for women’s hormone health, sexual health, skin, hair, and daily health.
Two structural facts matter before you spend a dollar. First, OMZO is not a medical practice or a pharmacy — its own terms say so directly. It does not employ healthcare providers. Prescriptions come from third-party networks of US-licensed clinicians, and state-licensed compounding pharmacies fill them. OMZO collects your monthly fee and pays those pharmacies itself.
Second, basic corporate facts are missing. The terms we reviewed in July 2026 list no legal entity name and no physical business address, and the governing-law clause refers vaguely to the state in which Omzo operates — without naming it. Established competitors publish this information. OMZO does not, and that gap cost it points in our rubric.
The marketing style is worth knowing, too. OMZO runs heavy advertising funnels, including multiple celebrity-themed landing pages built around Scott Disick, and most of the “reviews” you find in search results are paid newswire placements, not independent journalism. None of that makes the medication fake — but it means much of what you read about OMZO online was bought.
One thing OMZO gets right: its footer states plainly that its compounded drugs are not FDA-approved and that the FDA has not reviewed them for safety, effectiveness, or quality. That disclosure is accurate and legally required in spirit — and some competitors have drawn FDA warning letters for claiming otherwise.
OMZO Pricing in 2026
OMZO bundles everything into one monthly price: the telehealth consultation, prescription, medication, shipping, and ongoing support. There is no membership fee and no contract. These are the prices published in OMZO’s own Terms & Conditions as of July 2026.
| Program | First Month | Ongoing Price |
|---|---|---|
| Compounded semaglutide injection | $199 (advertised from $179) | $299/mo, flat at every dose |
| Compounded tirzepatide injection | $349 | $399/mo |
| Oral GLP-1 dissolvable tablets | From $249 | Not published |
| Brand-name Ozempic | $1,299/mo per terms | Site nav says from $1,999/mo |
| Brand-name Zepbound (vials) | $1,399/mo per terms | $1,399/mo |
Watch three things in that table. First, the promo-to-regular jump: semaglutide rises $100/month after month one ($199 to $299), and tirzepatide rises $50 ($349 to $399). The flip side is real, though — refills are locked at $299 flat, and we found no dose-based tiers anywhere. Your bill does not climb as you titrate up, which is more than dose-priced competitors can say.
Second, OMZO’s own pages disagree with each other. The funnel advertises the first month at $179, while the binding terms say it was originally priced at $179 and is currently offered at $199. Ozempic is listed at $1,299/month in the terms but “starting at $1,999/mo” in the site navigation. Neither gap is explained. When a company’s ads and its binding terms show different numbers, assume the terms win — and budget accordingly.
Third, the refund policy is much narrower than the marketing. OMZO’s funnel promotes an OMZO Guarantee with lose-weight-or-your-money-back framing. The binding terms allow refunds in exactly two cases: a clinician finds you medically ineligible, or there is a billing error. Orders become non-refundable once your medical intake is submitted. Two protections do survive the fine print: a full refund if medication has not shipped within 14 business days, and a full refund of consultation fees if you are not approved. Refund requests must be emailed within 28 days of payment.
At $299/month ongoing, OMZO lands mid-pack for compounded semaglutide. Several rivals in our cheap weight loss injections comparison start at $99–$149/month — though the cheapest providers carry complaint records that OMZO, so far, is simply too small to have earned.
How OMZO Works
The OMZO weight loss process follows the standard telehealth pattern, per its own site.
Step 1: Online questionnaire. You answer questions about your goals, medical history, and lifestyle. No insurance is needed — all OMZO prescriptions are cash-pay.
Step 2: Clinician review. Licensed clinicians from third-party provider networks review your intake and make the final determination on whether to prescribe. A prescription is never guaranteed, and if you are not approved, OMZO says you receive a full refund of any consultation fees paid.
Step 3: Pharmacy fulfillment. If approved, a state-licensed sterile compounding pharmacy ships your medication within 48 business hours of prescription approval. OMZO does not name these pharmacies or disclose whether they are 503A pharmacies or stricter 503B outsourcing facilities — a transparency gap that matters, because with compounded drugs the pharmacy is the product. The terms even note that products will not bear the Omzo name or logo.
Step 4: Delivery. Shipping is free, delivery typically takes 3–5 business days, and service covers all 50 states per the terms. If nothing ships within 14 business days, you are entitled to a full refund.
Step 5: Ongoing support. Care-team messaging runs through the Omzo app. You can cancel anytime — future charges stop, but charges already processed are non-refundable.
OMZO Review: What Results Can You Expect?
No honest OMZO review can quote you a personal number, and we do not test medications ourselves. The realistic baseline comes from clinical trials of the FDA-approved versions of these molecules. Weekly semaglutide 2.4 mg produced an average 14.9% body-weight loss over 68 weeks in the STEP 1 trial. Tirzepatide reached up to 20.9% average loss over 72 weeks at the highest dose in SURMOUNT-1. Both trials paired medication with diet and exercise changes.
Two caveats apply directly to OMZO. The compounded drugs it ships were not the products tested in those trials and are not FDA-approved — OMZO’s own terms warn that its compounded medication is not a generic version of an approved drug. And expect a slow ramp regardless of provider: the FDA-approved label titrates semaglutide from 0.25 mg up to 2.4 mg over roughly four months, so meaningful results build gradually.
As for documented customer experiences with OMZO specifically, there is almost nothing to weigh: about 7 Trustpilot reviews averaging 4 stars as of July 2026, no BBB file, and search results padded with paid placements. A 4-star average is fine — but a 7-review sample proves nothing in either direction, and that uncertainty is priced into our 6.9/10.
OMZO vs MEDVi
MEDVi (7.6/10) is the natural comparison: both sell compounded semaglutide that settles at a flat $299/month, both offer oral dissolvable tablets from $249, and neither charges a membership fee.
| Feature | OMZO | MEDVi |
|---|---|---|
| Our score | 6.9/10 (Fair) | 7.6/10 (Good) |
| Semaglutide | $199 first month, then $299/mo | $179 first month, then $299/mo |
| Tirzepatide | $349 first month, then $399/mo | From about $349/mo |
| Oral tablets | From $249 | From $249 first month |
| Pharmacies named? | No — unnamed, no 503A/503B disclosure | Yes: Triad Rx, RedRock, Beaker Pharmacy |
| Trustpilot | 4/5 across about 7 reviews | About 4.4/5 across roughly 14,000 reviews |
| BBB | No profile found | F rating, 662 complaints |
MEDVi wins this matchup on evidence. It starts $20 cheaper in month one, publicly names its three compounding pharmacies, and has a Trustpilot record roughly 2,000 times larger than OMZO’s. That record is not spotless — MEDVi’s BBB file shows an F rating with 662 complaints, which we unpack in our MEDVi review — but a documented mixed record still beats an empty one when you are mailing a company $299 every month. OMZO’s counterpunch is contractual: locked refill pricing stated in its terms and a clean 14-business-day shipping refund.
If the daily tablet is what draws you to either brand, compare the wider field first — our guide to oral GLP-1 options covers dissolvable tablets, sublingual drops, and the FDA-approved pills, with prices from $149/month.
Who Should Use OMZO — and Who Shouldn’t
Use OMZO if a locked refill price is your priority. Semaglutide at a flat $299/month with no membership fee, no contract, and no dose tiers is a clean, predictable bill. Dose-priced competitors can end up charging $100–$200 more per month by maintenance dose.
Use OMZO if you want injections and tablets in one storefront. The OMZO weight loss menu spans compounded injections, oral dissolvable tablets, tirzepatide, and brand-name paths — useful flexibility if you may switch formats later.
Skip OMZO if you buy on verifiable trust. Seven Trustpilot reviews, no BBB profile, unnamed pharmacies, and no disclosed legal entity is the thinnest paper trail of any provider we have scored. If that bothers you — and it is reasonable if it does — pay MEDVi’s identical $299 refill price and get 14,000 reviews and named pharmacies.
Skip OMZO if the money-back guarantee is your reason to buy. The binding terms do not honor weight-loss-based refunds, full stop. Buy on the price, not the promise.
Skip OMZO if you want the cheapest possible entry. Sprout Health sells compounded semaglutide from $149/month with a written price-lock and a sublingual option — though our Sprout Health review details its September 2025 FDA warning letter and BBB F rating, which is why it scores below OMZO at 6.4/10.
Standard qualification rules apply here as everywhere: telehealth providers generally require a BMI of 30+, or 27+ with a weight-related condition such as high blood pressure or type 2 diabetes. Expect disqualification for a personal or family history of medullary thyroid carcinoma or MEN 2, a history of pancreatitis, or current pregnancy.
Is OMZO Legit? Our Verdict
OMZO appears to be a real, operating telehealth platform — not a scam storefront. It publishes binding terms, correctly discloses that its compounded drugs are not FDA-approved, refunds applicants a clinician rejects, and puts a hard 14-business-day shipping deadline behind a refund right. Its bundled, flat-price model is honest in structure: one number, no membership, no dose creep.
But 6.9/10 (Fair) is the ceiling for a company this opaque, and the problems deserve plain language. OMZO does not name its compounding pharmacies or their 503A/503B status. Its terms omit a legal entity name and business address. Its ads say $179 while its terms say $199; its terms say Ozempic costs $1,299 while its navigation says $1,999. Its footer says it does not sell branded medications while its terms say it does, on a limited basis. Its guarantee marketing promises refunds its terms do not allow. And with roughly 7 independent reviews in existence, there is no customer record big enough to offset any of that.
How This OMZO Review Scored the Brand
Our score comes from the public 5-factor rubric on our How We Rank page: pricing transparency (30%), total cost (25%), safety and sourcing (20%), service flexibility (15%), and reputation (10%). OMZO earns real credit on total cost and flexibility — the flat $299 refill lock and the no-contract, no-membership structure are consumer-friendly — but it bleeds points on transparency (internal price contradictions, refund-marketing mismatch), sourcing (unnamed pharmacies), and reputation (a near-empty record). These are editorial ratings built from documented research — OMZO’s own terms, shipping and refund policies, and third-party review platforms checked in July 2026 — not first-hand drug testing, and not paid placement. If OMZO names its pharmacies and builds a real review history, this score can move; until then, Fair is exactly what the evidence supports.